Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rising prevalence of cancer and increasing adoption of personalized medicine to drive the growth of global neoantigen cancer vaccine market.
By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun, Others),
https://www.openpr.com/news/2315164/north-america-to-dominate-neoantigen-cancer-vaccine-market
Merck : Darmstadt, Germany, Initiates First Clinical Trial ...
https://www.marketscreener.com/quote/stock/MERCK...
Jun 25, 2020 · Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. The Company will initiate a Phase II randomized, controlled clinical study evaluating ...
Estimated Reading Time: 4 mins
Missing: virosomes Must include: virosomes
they changed missing virosomes to Must include Virosomes
https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-Darmstadt-Germany-Initiates-First-Clinical-Trial-of-TLR7-and-8-Inhibitor-as-a-Potential-Tr-30823644/
MORRISON & FOERSTER Law Firm Profile - Patexia
https://www.patexia.com/lawfirm/morrison-foerster/patents
Application number Title of the patent IPC Filing Date Decision Date; 17409050 : Oral dispersible vaccine comprising virosomes : A61K : Aug 22, 2021 : Jan 17, 2022
https://www.patexia.com/lawfirm/morrison-foerster/patents
Virosome-based nanovaccines; a promising bioinspiration ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750
Jul 01, 2021 · Virosomes have been emerging as FDA approved nanocarriers for human use due to their excellent tolerance and safety profile (8–10). Subunit vaccines presented poor performance against viral invasions, while virosomes create strong humoral and cellular immune responses similar to a potent adjuvant.
Author: Khatereh Asadi, Ahmad Gholami
Publish Year: 2021
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Reinhard Glüek the man that spent a life time on VIROSOMES!!!!!!!!!
LETS GET THIS DONE KEMPERS IN HONOR OF HIM!!!!!!!!!!!!!
Reinhard Glüek, Executive Vice President R&D, Vaccine Discovery
https://isirv.org/site/index.php/10-board/53-reinhard-glueek
https://isirv.org/site/images/stories/downloads/Reinhard_Gluck_-_Biosketch.pdf
The death of Reinhard Glueck, president of Etna Biotech. The condolences of the city of Caltagirone
By
Editing
20 April 2021
We are strongly and sincerely sorry for the passing of Dr. Glueck (pictured), an internationally renowned scientist and far-sighted industrialist who had chosen Caltagirone as the place of choice. We still remember his, as always, lucid and punctual intervention on the occasion of the days dedicated to the bioeconomy last September, in Caltagirone. With her death, our city loses the precious point of reference of a man who loved her deeply, as well as her family members, to whom our heartfelt condolences go". This was underlined by the mayor Gino Ioppolo recalling Reinhard Glueck, microbiologist president of Etna Biotech, Caltagironese by adoption (he lived in the city of ceramics with his family). The president of the City Council Massimo Alparone: "He had already spent and continued to spend himself for Sicily and the territory in which he had decided to live together with his loved ones demonstrating a great attachment to our Caltagirone".
https://www.lagazzettadelcalatino.it/2021/04/la-morte-di-reinhard-glueck-presidente-di-etna-biotech-il-cordoglio-della-citta-di-caltagirone/
Mymetics using HLA
Mario Amacker currently works at the Quality and Manufacturing Management of Mymetics SA and Mymetics BV. ... Expression of surface molecule markers HLA-[/b]DR, CD40, CD80, CD86, CD163
May 18, 2020 · Cells that are HLA-DR + CD11c + CD1c + CD1a + have a phenotype similar to ... (1 µg/mL) or rgp41 (0.5 µg/mL) provided by Mymetics SA were diluted in coating buffer
Immatics Biotechnologies GmbH Using HLA
Immatics scientists and collaborators present functionally empty and peptide-receptive HLA-
IMMATICS BIOTECHNOLOGIES GMBH: TUBINGEN: DE: Family ID: 49767624: Appl. No.: 14/531472: ... and N-terminal amino acids 1-80 of HLA-DR antigen-associated invariant
https://www.patentguru.com/search?q=virosomes
www.freepatentsonline.com › y2020 › 0085930PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY ...
Immatics Biotechnologies GmbH (Tuebingen, DE) ... [PLG]-based and dextran microparticles, talactoferrin SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF ...
Author: Andrea Mahr, Oliver Schoor, Toni Weinschenk
Publish Year: 2017
https://www.freepatentsonline.com/y2020/0085930.html
Hmmm! Immatics Biotechnologies based out of Germany and Texas!!!!!!!!!
Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.
Airouche, Sabi; Beltrami, Vanya; Fleury, Sylvain; Batard, Thierry; Bordas-Le Floch, Véronique; Stegmann, Toon; Amacker, Mario; Kettner, Alexander; Mascarell, Laurent (2021). Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice. Clinical and experimental allergy, 51(2), pp. 339-349. Wiley 10.1111/cea.13814
METHODS
Virosomes with membrane-integrated contiguous overlapping peptides (COPs) of Bet v 1 and TLR4 or TLR2/TLR7 agonists were assessed for induction of Bet v 1-specific IgG1, IgG2a and IgE antibodies, hypersensitivity reactions and body temperature drop following subcutaneous injection in naive CD-1 mice. The most promising candidate, Bet v 1 COPs anchored to virosomes with membrane-incorporated TLR4 agonist (Vir.A-Bet v 1 COPs), was further evaluated by the sublingual route in a therapeutic setting in BALB/c mice with birch pollen-induced allergic asthma. Airway hyperresponsiveness, pro-inflammatory cells in bronchoalveolar lavages and polarization of Th cells in the lungs and spleen were then assessed.
RESULTS
Both types of adjuvanted virosomes coupled to Bet v 1 COPs triggered a boosted Th1 immunity. Given a more favourable safety profile, Vir.A-Bet v 1 COPs were further evaluated and shown to able to fully reverse asthma symptoms and lung inflammation in a sublingual therapeutic model of birch pollen allergy.
CONCLUSIONS AND CLINICAL RELEVANCE
We report herein for the first time on the capacity of a novel and safe presentation platform, that is virosomes with membrane-integrated TLR4 agonist, to improve dramatically sublingual AIT efficacy in a murine model due to its intrinsic dual properties of targeting and stimulating to further promote anti-allergic immune responses. As such, our study paves the ground for further clinical development of this allergen presentation platform for patients suffering from respiratory allergies.
https://boris.unibe.ch/157439/
https://boris.unibe.ch/cgi/search/simple?q=virosome&_action_search=Search&_action_search=Search&_order=bytitle&basic_srchtype=ALL&_satisfyall=ALL&limit=5
Nanovaccines in the Fight Against Infectious Disease
Download PDF Copy
Request Quote
Hussain Ahmed
By Hussain Ahmed Dec 7 2021
Reviewed by Megan Craig, M.Sc.
The development and clinical uses of nanomaterials-based vaccine delivery systems to suppress viral infections such as COVID-19, which may have disastrous socio-economic implications, were studied in a recent study published in the journal Pharmaceutics.
https://www.azonano.com/news.aspx?newsID=38323
Liposomes MeSH Descriptor Data 2022
https://meshb.nlm.nih.gov/record/ui?ui=D008081
https://meshb.nlm.nih.gov/record/ui?ui=D022701
www.ncbi.nlm.nih.gov › pmc › articlesPubMed Central, Table 2: Bionanoscience. 2022 Jan 26 : 1–18 ...
Virosomes or artificial viruses • Composed of reconstituted viral proteins structurally : Stealth liposomes • Carrier surface covered with hydrophilic chains [PEG] • Bypasses phagocytosis and aids
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790012/table/Tab2/
taggs.hhs.gov › Detail › Award Detail Award Information | HHS TAGGS
Jan 13, 2022 · Two independent nonhuman primate (NHP) studies demonstrated the safety and high efficacy of the combination of virosome-P1 + virosome rgp41 against repeated low-dose
https://taggs.hhs.gov/Detail/AwardDetail?arg_AwardNum=U19AI142636&arg_ProgOfficeCode=104
vaccines given by selected mucosal routes – and generate GMP vaccine for a Phase I trial to be conducted with the HVTN. Our vaccine development plans represent major advances, as the novel needle-free, solid vaccine dosage forms are cold-chain independent and will be mucosally delivered – unique aspects that make the novel virosomal vaccines especially attractive for the developing world, where the AIDS epidemic remains a serious problem.
Hey! Kempers what about the big Bonanza
https://images.search.yahoo.com/yhs/search?p=big+bonanza&fr=yhs-frontier-frontier1&type=frontier_pc_homerun_portal&hspart=frontier&hsimp=yhs-frontier1&imgurl=http%3A%2F%2Fwww.boyactors.org.uk%2Fposters%2F2999.jpg#id=87&iurl=https%3A%2F%2Fwww.insp.com%2Fcontent%2Fuploads%2F2013%2F09%2F20-DCSM-0622_Showpage_eBanners-Bonanza1200x628.jpg&action=click
getting to be an old man Kemp's is. Most of been the pressure from the peeps here.
Merry Christmas to all here, You are all good Friends!!
www.nejm.org › doi › pdfDeveloping Covid-19 Vaccines at Pandemic Speed
Mar 30, 2020 · The NEW ENGLAND JOURNAL of MEDICINE May 21, 2020 ... University of Queensland/GSK/ Baylor College of Medicine iBio/CC-Pharming ... and WRAIR Walter Reed Army
https://www.nejm.org/doi/pdf/10.1056/NEJMp2005630?articleTools=true
Transvac 2 is a new virosomal vaccine designed
www.ncbi.nlm.nih.gov › pmc › articlesVirosome-based nanovaccines; a promising bioinspiration and ...
Jul 01, 2021 · Especial efforts should be put on virosome-based viral vaccine improvements and further tests to accelerate the approval process. Transvac 2 is a new virosomal vaccine designed against sarscov2 viruses that are in phase ?? clinical trials. The transvac 2 vaccine is an innovative compound expected to be helpful in the recent viral pandemic.
Author: Khatereh Asadi, Ahmad Gholami
Cited by: 2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Nasri Nahas
Membre du Conseil de Fondation at CHUV | Lausanne university hospital
https://www.arounddeal.com/profile/nasri-nahas/t2cwheeuty/
interesting:
https://www.biopole.ch/story/hiv-epidemic-treatments-whats-going-on/
Nasri’s profile photo
Nasri Nahas likes this
Biopôle Lausanne
Biopôle Lausanne
5,789 followers
1w • Edited • 1 week ago
Follow
??It's been 40 years!
40 years since scientists discovered #HIV. Since then, researchers worked hard to find a treatment. And thanks to them, HIV is now considered a chronic disease where treated patients manage to control their viral load and live long. But while antiretroviral therapy has been huge progress, the fight against HIV is not over.
HIV is still a major global health issue and a cure and/or preventive treatment is still necessary. And while developing such treatment has proven to be challenging, companies like Mymetics Corporation are working hard on that topic, using an innovative approach to develop a #vaccine against HIV.
In our interview with Ronald Kempers, CEO and CFO of Mymetics, we discussed their vaccine development: https://bit.ly/HIVMymetics
https://www.biopole.ch/story/biopoles-entrepreneurs-share-journey-and-tips-from-ronald-kempers-ceo-and-cfo-at-mymetics/
Vaccine development and production
Parent Project Number
5U19AI142636-03
Sub-Project ID
6242
Contact PI/Project Leader
FLEURY, SYLVAIN
Awardee Organization
UNIVERSITY OF LOUISIANA AT LAFAYETTE
https://reporter.nih.gov/search/a47Br7mlpEuFZCaZwwvReg/project-details/9919549
https://www.pubfacts.com/author/Sylvain+Fleury
oncologypro.esmo.org › content › downloadAdoptive cell therapy in the era of immune checkpoint blockade
GnTV VLP GnT-V VLP10mer Me loe-1 TLN Telome ra se RLF ... – Inge Marie Svane: HerlevHospital, Copenhagen, Phase II trial in refractory MM patients • Lion .
https://oncologypro.esmo.org/content/download/109542/1928269/file/2017-ESMO-Preceptorship-Immuno-Oncology-Adoptive-T-Cell-Transfer-BAG-Haanen.pdf
Virosome vaccines and their application in cancer immunotherapy
A. Homhuan
Published 2009
Biology
Asian Biomedicine
Background: An increasing number of tumor associated antigens (TAA) capable of inducing immune responses have been identified in the last two decades. Unfortunately, they are weak immunogens and require potent adjuvants to promote their immunogenicity. Virosomes, nano-lipid vesicles containing viral protein spikes, have been proven amenable for transferring antigen (Ag) to the major histocompatibility complex (MHC) class I processing pathway with the aim to prime cytotoxic T-ymphocytes (CTL) responses. Objective: This mini-review outlines the virosomes platform, ranging from virosomal preparation, their intracellular trafficking and mechanism of action. Methods: The review is directed toward an application of virosomes as a novel and potential vaccine adjuvant in active cancer immunotherapy. Results and conclusion: Virosomes have been proven to be a suitable TAA delivery carrier. Ag encapsulated inside the lumen of virosomes could be prevented from serum- and cell-associated peptidases. Virosomes also facilitated the intracellular trafficking of encapsulated Ag, in which Ag could reach the cytosol and be presented by the MHC-Class I machinery. In addition, virosomes with TAA encapsulated are amenable to be a novel tumor immunotherapeutic strategy.
https://www.semanticscholar.org/paper/Virosome-vaccines-and-their-application-in-cancer-Homhuan/0d2714bb663b79686d957b4d3366c7a1aa71170b
www.researchgate.net › publication › 330543268(PDF) Vaccine Strategies to Improve Anti-cancer Cellular ...
Jan 22, 2019 · Virosomes and virus-like ... NCT03047928 Combination Therapy With Nivolumab and PD-L1/IDO. ... PD-L1/IDO peptide vaccine Phase. 1/2 (G) Cancer Vaccine + Epigenetic
https://www.researchgate.net/publication/330543268_Vaccine_Strategies_to_Improve_Anti-cancer_Cellular_Immune_Responses
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-efficacy-and-immunity-of-combination-therapy-with-nivolumab-and-ido-pd-l1-peptide-vaccine-in-patients-with-metastatic-melanoma-a-phase-i
Conclusions
The combination of IDO/PD-L1 peptide vaccine and nivolumab is safe with encouraging early efficacy data; an ORR of 79% was reached and 45% achieved complete response. Vaccine specific T-cells were demonstrated in PBMCs and tumor site. ClinicalTrials.gov Identifier: NCT03047928 1 IO Biotech (www.iobiotech.com) has licensed the patent of the vaccine IO102/IO103 T-win®.
Background: An increasing number of tumor associated antigens (TAA) capable of inducing immune responses have been identified in the last two decades. Unfortunately, they are weak immunogens and require potent adjuvants to promote their immunogenicity. Virosomes, nano-lipid vesicles containing viral protein spikes, have been proven amenable for transferring antigen (Ag) to the major histocompatibility complex (MHC) class I processing pathway with the aim to prime cytotoxic T-ymphocytes (CTL) responses. Objective: This mini-review outlines the virosomes platform, ranging from virosomal preparation, their intracellular trafficking and mechanism of action. Methods: The review is directed toward an application of virosomes as a novel and potential vaccine adjuvant in active cancer immunotherapy. Results and conclusion: Virosomes have been proven to be a suitable TAA delivery carrier. Ag encapsulated inside the lumen of virosomes could be prevented from serum- and cell-associated peptidases. Virosomes also facilitated the intracellular trafficking of encapsulated Ag, in which Ag could reach the cytosol and be presented by the MHC-Class I machinery. In addition, virosomes with TAA encapsulated are amenable to be a novel tumor immunotherapeutic strategy.
https://www.researchgate.net/publication/228346372_Virosome_vaccines_and_their_application_in_cancer_immunotherapy
The objective of the project is to evaluate the suitability of Mymetics’ proprietary virosome vaccine
delivery technology in combination with IO Biotech’s T-win® technology. IO Biotech will provide
Mymetics with their proprietary peptide based antigen (Ag) which Mymetics will link to its virosomebased vaccine carrier and produce several formulations. IO Biotech will then compare, Ag-Virosomes,
Ag alone, Virosomes alone to other control groups in a preclinical therapeutic tumor model.
Mymetics Starts Research Project in Cancer Immunotherapy with IO Biotech
- Exploratory project to compare IO Biotech antigens linked to Mymetics’ virosomes in a
preclinical tumor model
Virosome vaccines and their application in cancer immunotherapy
Ag encapsulated inside the lumen of virosomes could be prevented from serum- and cell-associated peptidases. Virosomes also facilitated the intracellular trafficking of encapsulated Ag,
A digital DNA-designing platform ensures a straightforward design process and efficient production of new vaccine vectors, the press release explains. Moreover, the process can be quickly adapted to viral mutations. Allergic reactions are avoided, while the vaccine remains stable for longer at room temperature.
https://www.s-ge.com/en/article/news/20212-life-science-innosuisse-funding-rocketvax
Virosomes without cationic lipids also improved induction of cellular immunity by pDNA but to a significantly lower extent than CIV. These findings suggest that pDNA-CIV complexes could be an efficacious delivery system suitable for CTL induction by DNA vaccination.
https://pubmed.ncbi.nlm.nih.gov/22981929/
Wyss Institute researchers predict the biggest scientific advances of the 2020s
https://news.harvard.edu/gazette/story/2020/01/wyss-researchers-predict-biggest-scientific-advances-of-2020s/
Batavia to Develop Clinical Process for RocketVax’s COVID-19 Vaccine
contractpharmaJuly 09, 2021
Tag: Batavia , ROCKETVAX , RVX-13 , COVID-19
https://www.pharmasources.com/news/71752.html
https://www.cmocro.com/news_detail/Batavia+Biosciences+to+Develop+Innovative+Clinical+Process+f/606291/index.html
With start-up funding of CHF 1 million, the USB will enable the continuation of the preclinical research work on the new vaccine that has already begun. The University of Basel and Swiss TPH participate by providing their research infrastructure and human resources. The Canton of Basel-Stadt is supporting this research cooperation with a further million Swiss francs. Both Switzerland and abroad could benefit from a vaccine produced in the Basel region, according to the USB. The first six-month project phase was funded by Innosuisse with CHF 1.2 million.
RocketVax's vaccine uses coronavirus-based vectors. What distinguishes it is that, unlike the first-generation vaccines, which only target the spike protein, it presents the immune system with a wide range of components of the SARS-CoV-2 virus. This should provoke a much broader antibody response and reduce the risk of viral escape mechanisms. Due to a built-in "error", however, it can not multiply, so it is not infectious.
https://www.s-ge.com/de/article/aktuell/20212-life-science-rocketvax-coronavirus-vaccine
Show me something here Dr. Thomas Staehelin ??????
Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
https://www.dkoding.in/press-release/swiss-rockets-ag-announces-the-founding-of-rocketvax-for-the-development-of-a-next-generation-sars-cov-2-vaccine/
Dr. Thomas Sander
Member of Scientific and Drug Discovery Advisory Committee & Founder
https://swissrockets.com/#company
Dr. Thomas Staehelin
https://rocketvax.com/
https://rocketvax.com/#partners-section
https://rocketvax.com/news/
Mario Amacker
Mymetics Corporation
Total Duration 7 yrs
Title Project Manager for SARS-CoV-2 Vaccine
Full-time
Dates Employed Apr 2020 – Present
Employment Duration1 yr 6 mos
Location Lausanne, Waadt, Schweiz
Title Head of Quality & Manufacturing
Dates Employed2014 – Present
Employment Duration7 yrs
Location Epalinges / Lausanne, Switzerland
Member of the Executive Management
Specialized know-how in VLP development
- CMC: Process Development, Manufacturing & Quality control and QA
Planning and coordination of manufacturing of product candidates (development strategy, CRO/CMO selection and supervision, project management, quality and costs), and documentation (development reports). Contact with external clients for manufacturing relevant issues. Life cycle management.
- Selection, negotiation and management of outsourced services.
- All QC relevant issues: QC method development & validation (ICH Q2, PDA), incoming control, IPC & release testing (excipients & final products), stability plans & studies (ICH Q5C,Q1A), including product storage (GSP) and transport (GDP), implementation of new analytical methods, method transfers, product comparability testing, external audits of CROs (anal. service labs), support of QA and Regulatory dept, documentation (SOPs, reports), contact with external clients for QC relevant issues.
- QA relevant issues: Establishment of regulatory documents (IMPD, IND), quality agreements, risk analysis (ICH Q9), set-up of product specifications, external audits of CMOs and suppliers, product storage (GSP) and transport (GDP). Support of QP in official audits (e.g. Swissmedic, 3rd parties).
Virus-like particles: preparation, immunogenicity and their ...
Feb 25, 2021 · Nipah virus VLPs can be formed in HEK293T cells expressing the virus attachment glycoprotein (G), fusion (F) glycoprotein and matrix (M) protein . Mice vaccinated with NiP VLPs
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905985/
Mymetics Corporation reports progress with malaria vaccine ...
www.proactiveinvestors.com › companies › news
Apr 05, 2016 · Mymetics Corporation (OTCQB:MYMX), a developer of vaccines designed to halt the transmission of human infectious diseases, has reported success in a malaria blocking study. Virosome vaccine candidates tested were able to significantly reduce ( (97-100%) the transmission of the Plasmodium falciparum parasite at the highest dose.
Then why has this not been to market? MR.K
Vaccination is the most effective means of controlling infectious disease-related morbidity and mortality.
However, due to low immunogenicity of viral antigens, nanomedicine as a new opportunity in new generation
of vaccine advancement attracted researcher encouragement. Virosome is a lipidic nanomaterial emerging as
FDA approved nanocarriers with promising bioinspiration and biomimetic potency against viral infections.
Virosome surface modification with critical viral fusion proteins is the cornerstone of vaccine development.
Surface antigens at virosomes innovatively interact with targeted receptors on host cells that evoke humoral
or cellular immune responses through antibody-producing B cell and internalization by endocytosis-mediated
pathways. To date, several nanovaccine based on virosome formulations have been commercialized against
widespread and life-threatening infections. Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Thus, this review provides a novel overview of the virosome based nanovaccine production, properties, and application on
the viral disease, especially its importance in SARS-CoV-2 vaccine discovery.
© 2021 Elsevier B.V. All rights reserved.
https://kb4.ingentium.com/scoutData/references/covkb/pdf/61487.pdf
https://covkb.ingentium.com/evidence/references/61752
Mosquito Repellent Bracelets hand Wrist Band telephone Ring Chain Anti-mosquito bracelet Pest Control Bracelet Bands KKA1935
Sorry,Currently unavailable
https://www.dhgate.com/product/10pcs-pack-mosquito-repellent-bracelets-multicolor/414336263.html
Research unit INNOSUISSE
Project number 49697.1 IP-LS
Project title Characterizing the respiratory tract immune response after nasal COVID-19 vaccination
Basic data Texts Participants
Texts for this project
German French Italian English
Short description
Anzeigen
-
-
Anzeigen
Abstract
Anzeigen
-
-
Anzeigen
Inserted texts
Category Text
Short description
(German)
Characterizing the respiratory tract immune response after nasal COVID-19 vaccination
Short description
(English)
Characterizing the respiratory tract immune response after nasal COVID-19 vaccination
Abstract
(German)
Characterizing the nasal COVID-19 vaccine-induced immune responses in the blood, nose and lungs of young and mid-age adult rats to confirm the virosomes-RBD vaccine safety, tolerate, while eliciting protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.
Abstract
(English)
https://www.aramis.admin.ch/Texte/?ProjectID=47917
https://www.aramis.admin.ch/Grunddaten/?ProjectID=47917
100 % T490 Biotechnology
Category Text
Short description
(English)
The Body on a Chip.
Abstract
(English)
In contrast to state-of-the-art 2D culturing technologies, which do not reflect the characteristics and functionality of intact tissues or whole organs, we propose here a simple and cost-effective way to achieve (a) biomimetic 3D cultures and (b) co-culturing of different tissue types in a functional arrangement. The final goal is a chip/microfluidics design that mimics the organism`s physiology and the interplay of the individual tissues so that the effects of specific interventions can be tested with a higher predictability in drug development, diagnostics or personalized medicine ('The Body on a Chip').
https://www.aramis.admin.ch/Texte/?ProjectID=26799
Mymetics call them self a vaccine company! What vaccine has gone to market?
:(